Table 1.
Clinical characteristics of the PDAC patient cohort (n = 58).
| Treatment response | Disease control (n = 48) | Progressive disease (n = 10) | P value | Total cohort (n = 58) |
|---|---|---|---|---|
| RECIST1.1 after four cycles, n (%) | ||||
| Partial response | 12 (25) | 0 (0) | – | 12 (21) |
| Stable disease | 36 (75) | 0 (0) | 36 (62) | |
| Progressive disease | 0 (0) | 10 (100) | 10 (17) | |
| Disease stage, n (%) | ||||
| (Borderline) resectable disease | 18 (38) | 2 (20) | 0.51 | 20 (34) |
| Locally advanced (LAPC) | 18 (38) | 6 (60) | 24 (41) | |
| Metastatic disease | 12 (25) | 2 (20) | 14 (24) | |
| Median age [min, max] | 65 [48, 78] | 62 [47, 68] | 0.19 | 64 [47, 78] |
| Median BMI (kg/m2) [min, max] | 25 [16, 36] | 25 [19, 36] | 0.91 | 25 [16, 36] |
| Sex, n (%) | ||||
| Female | 23 (48) | 4 (40) | 0.74 | 27 (47) |
| Male | 25 (52) | 6 (60) | 31 (53) | |
| Alcohol use, n (%) | ||||
| Current | 23 (48) | 3 (30) | 0.57 | 26 (45) |
| Former | 7 (15) | 2 (20) | 9 (16) | |
| Never | 18 (38) | 5 (50) | 23 (40) | |
| Smoking status, n (%) | ||||
| Current | 11 (23) | 2 (20) | 1.0 | 13 (22) |
| Former | 18 (38) | 4 (40) | 22 (38) | |
| Never | 19 (40) | 4 (40) | 23 (40) | |
| Diabetes Mellitus, n (%) | ||||
| No | 38 (79) | 7 (70) | 0.68 | 45 (78) |
| Yes | 10 (21) | 3 (30) | 13 (22) | |
| History of malignancy, n (%) | ||||
| No | 42 (88) | 8 (80) | 0.62 | 50 (86) |
| Yes | 6 (12) | 2 (20) | 8 (14) | |
| History of pancreatitis, n (%) | ||||
| No | 46 (96) | 9 (90) | 0.44 | 55 (95) |
| Yes | 2 (4) | 1 (10) | 3 (5) | |
| CA19-9 (U/mL), median [min, max] | ||||
| Before first cycle | 294 [0, 26500] | 418 [4, 83300] | 0.41 | 294 [0, 83300] |
| After first cycle | 207 [0, 35700] | 380 [5, 85200] | 0.28 | 207 [0, 85200] |
| Absolute change | 5 [-5860, 9260] | 13 [-3670, 4070] | 0.46 | 9 [-5860, 9260] |
| Non-expressors, n (%) | 8 (17) | 0 (0) | 8 (14) | |
| CEA (ng/L), median [min, max] | ||||
| Before first cycle | 4.1 [0.8, 119] | 3.8 [0.7, 226] | 0.61 | 4.1 [0.7, 226] |
| After first cycle | 5.4 [0.9, 139] | 6.0 [1.2, 241] | 0.36 | 5.9 [0.9, 241] |
| Absolute change | 0.4 [-13, 20] | 0.7 [-2.8, 15] | 0.18 | 0.5 [-13, 20] |
| Missing, n (%) | 10 (21) | 1 (10) | 11 (19) | |
| NLR, before first cycle, median [min, max] | ||||
| Before first cycle | 3.1 [1.1, 20] | 3.2 [1.7, 6.9] | 0.45 | 3.3 [1.2, 20] |
| After first cycle | 4.9 [1.6, 20] | 3.2 [0.9, 7.6] | 0.24 | 4.9 [0.9, 20] |
| Absolute change | 1.7 [-13, 15] | 0.8 [-2.0, 4.3] | 0.31 | 1.4 [-13, 15] |
| Missing, n (%) | 6 (13) | 3 (30) | 9 (16) | |
| SII, before first cycle, median [min, max] | ||||
| Before first cycle | 870 [264, 7250] | 1010 [468, 2380] | 0.27 | 881 [264, 7250] |
| After first cycle | 1110 [366, 2870] | 962 [202, 2710] | 0.63 | 1070 [202, 2870] |
| Absolute change | 193 [-6180, 1750] | 196 [-1530, 1690] | 0.94 | 194 [-6180, 1750] |
| Missing, n (%) | 6 (13) | 3 (30) | 9 (16) | |
| Median FOLFIRINOX cycles [min, max] | 8 [3, 10] | 4 [1, 8] | < 0.001 | 8 [1, 10] |
Abbreviations: BMI, Body Mass Index; CEA, Carcinoembryonic Antigen; NLR, Neutrophil-to-Lymphocyte Ratio; RECIST1.1, Response Evaluation Criteria In Solid Tumors 1.1; SII, Systemic Immune-Inflammatory Index.